Pfizer subsidiary Parker Tennessee has completed its tender offer for all outstanding shares of common stock of US-based King Pharmaceuticals at $14.25 per share.

The offering period and withdrawal rights expired on 28 January 2010, and 92.5% of the outstanding shares of common stock were validly tendered and not validly withdrawn.

Pfizer intends to complete the acquisition through a short-form merger under Tennessee law on 28 February, and individuals designated by Pfizer will constitute a majority of the King board of directors.

Upon completion, King will become a wholly-owned subsidiary of Pfizer and common stock will cease to be traded on the New York Stock Exchange.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData